Current methods for the assessment and management of taxane-related neuropathy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Smith EM;Smith EM
  • Source:
    Clinical journal of oncology nursing [Clin J Oncol Nurs] 2013 Feb; Vol. 17 Suppl, pp. 22-34.
  • Publication Type:
    Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Oncology Nursing Press Country of Publication: United States NLM ID: 9705336 Publication Model: Print Cited Medium: Internet ISSN: 1538-067X (Electronic) Linking ISSN: 10921095 NLM ISO Abbreviation: Clin J Oncol Nurs
    • Publication Information:
      Original Publication: Pittsburgh, PA : Oncology Nursing Press, [1997-
    • Subject Terms:
      Antineoplastic Agents, Phytogenic/*adverse effects ; Breast Neoplasms/*drug therapy ; Peripheral Nervous System Diseases/*chemically induced ; Taxoids/*adverse effects; Antineoplastic Agents, Phytogenic/therapeutic use ; Breast Neoplasms/nursing ; Female ; Humans ; Patient Education as Topic/methods ; Peripheral Nervous System Diseases/physiopathology ; Taxoids/therapeutic use
    • Abstract:
      Taxane-induced peripheral neuropathy (TIPN) affects a number of patients with breast cancer. To properly manage these patients, nurses must be able to identify and assess TIPN, as well as educate patients on TIPN as a side effect of taxane therapy. This article provides practical suggestions regarding how nurses can incorporate clinically feasible measurement approaches into practice and includes examples of grading TIPN that illustrate the limitations of the current tools and techniques for assessment. For example, a shortened and revised version of the Total Neuropathy Score and the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity subscale should be considered for future use. In addition, neuropathy-related results from numerous phase III trials in breast cancer are discussed, and the latest evidence regarding pharmacologic interventions for TIPN is briefly summarized.
    • Accession Number:
      0 (Antineoplastic Agents, Phytogenic)
      0 (Taxoids)
    • Publication Date:
      Date Created: 20130131 Date Completed: 20131118 Latest Revision: 20140415
    • Publication Date:
      20231215
    • Accession Number:
      10.1188/13.CJON.S1.22-34
    • Accession Number:
      23360700